参考文献/References:
[1] In China TWCOTROCHAD,Hu SS. Report on cardiovascular health and diseases in China 2021:an updated summary [J]. J Geriatr Cardiol,2023,20(6):399-430.
[2] Cai A,Qiu W,Zhou Y,et al. Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction:results from the China Cardiovascular Association Database-Heart Failure Center Registry[J]. Eur J Heart Fail,2022,24(11):2048-2062.
[3] Savarese G,Stolfo D,Sinagra G,et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol,2022,19(2):100-116.
[4] Dewan P,Solomon SD,Jhund PS,et al. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF [J]. Eur J Heart Fail,2020,22(7):1247-1258.
[5] Solomon SD,Vaduganathan M,Claggett BL,et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction:DELIVER trial[J]. JACC Heart Fail,2022,10(3):184-197.
[6] Ismayl M,Abbasi MA,Al-Abcha A,et al. Sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction:a systematic review and meta-analysis of randomized controlled trials[J]. Curr Probl Cardiol,2023,48(5):101597.
[7] Cao H,Rao X,Jia J,et al. Effects of sodium-glucose co-transporter-2 inhibitors on kidney,cardiovascular,and safety outcomes in patients with advanced chronic kidney disease:a systematic review and meta-analysis of randomized controlled trials[J]. Acta Diabetol,2023,60(3):325-335.
[8] Wheeler DC,Stefánsson BV,Jongs N,et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol,2021,9(1):22-31.
[9] DeFronzo RA,Reeves WB,Awad AS. Pathophysiology of diabetic kidney disease:impact of SGLT2 inhibitors[J]. Nat Rev Nephrol,2021,17(5):319-334.
[10] 周京敏,王华,黎励文. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023 [J]. 中国循环杂志,2023,38(4):375-393.
[11] Griffin M,Rao VS,Ivey-Miranda J,et al. Empagliflozin in heart failure:diuretic and cardiorenal effects[J]. Circulation,2020,142(11):1028-1039.
[12] Shiina K,Tomiyama H,Tanaka A,et al. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure:a subanalysis of the CANDLE trial[J]. Hypertens Res,2023,46(2):495-506.
[13] Sakai T,Miura S. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction—Novel prospective cohort study[J]. Circ Rep,2019,1(7):286-295.
[14] Shim CY,Seo J,Cho I,et al. Randomized,controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus:the IDDIA trial[J]. Circulation,2021,143(5):510-512.
[15] Connelly KA,Zhang Y,Visram A,et al. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction[J]. JACC Basic Transl Sci,2019,4(1):27-37.
[16] Moellmann J,Klinkhammer BM,Droste P,et al. Empagliflozin improves left ventricular diastolic function of db/db mice[J]. Biochim Biophys Acta Mol Basis Dis,2020,1866(8):165807.
[17] Sanders-van Wijk S,van Empel V,Davarzani N,et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction[J]. Eur J Heart Fail,2015,17(10):1006-1014.
[18] Kolijn D,Pabel S,Tian Y,et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation [J]. Cardiovasc Res,2021,117(2):495-507.
[19] Kondo H,Akoumianakis I,Badi I,et al. Effects of canagliflozin on human myocardial redox signalling:clinical implications[J]. Eur Heart J,2021,42(48):4947-4960.
[20] Takahara S,Soni S,Maayah ZH,et al. Ketone therapy for heart failure:current evidence for clinical use[J]. Cardiovasc Res,2022,118(4):977-987.
[21] Santos-Gallego CG,Requena-Ibanez JA,San Antonio R,et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. J Am Coll Cardiol,2019,73(15):1931-1944.
[22] Li X,Lu Q,Qiu Y,et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure[J]. J Am Heart Assoc,2021,10(6):e018298.
[23] 刘海浪,张立,胡婷婷,等. 达格列净保护缺血性心力衰竭大鼠心脏的微小RNA表达谱系研究 [J]. 中国心血管杂志,2021,26(5):477-482.
[24] Triposkiadis F,Xanthopoulos A,Starling RC,et al. Obesity,inflammation,and heart failure:links and misconceptions[J]. Heart Fail Rev,2022,27(2):407-418.
[25] Lee TM,Chang NC,Lin SZ. Dapagliflozin,a selective SGLT2 inhibitor,attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med,2017,104:298-310.
[26] Abdollahi E,Keyhanfar F,Delbandi AA,et al. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages[J]. Eur J Pharmacol,2022,918:174715.
[27] Kang S,Verma S,Hassanabad AF,et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts:novel translational clues to explain EMPA-REG OUTCOME results[J]. Can J Cardiol,2020,36(4):543-553.
[28] Lee HC,Shiou YL,Jhuo SJ,et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats[J]. Cardiovasc Diabetol,2019,18(1):45.
[29] Varadhan A,Stephan K,Gupta R,et al. Growing role of SGLT2i in heart failure:evidence from clinical trials[J]. Expert Rev Clin Pharmacol,2022,15(2):147-159.
[30] Mazer CD,Hare GMT,Connelly PW,et al. Effect of empagliflozin on erythropoietin levels,iron stores,and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease[J]. Circulation,2020,141(8):704-707.
[31] Ghanim H,Abuaysheh S,Hejna J,et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis[J]. J Clin Endocrinol Metab,2020,105(4):dgaa057.
[32] Fuchs Andersen C,Omar M,Glenth?j A,et al.Effects of empagliflozin on erythropoiesis in heart failure:data from the Empire HF trial[J]. Eur J Heart Fail,2023,25(2):226-234.
[33] Nalliah CJ,Bell JR,Raaijmakers AJA,et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality[J]. J Am Coll Cardiol,2020,76(10):1197-1211.
[34] van Woerden G,van Veldhuisen DJ,Manintveld OC,et al. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction[J]. Circ Heart Fail,2022,15(3):e009238.
[35] Rossi VA,Gruebler M,Monzo L,et al. The different pathways of epicardial adipose tissue across the heart failure phenotypes:from pathophysiology to therapeutic target[J]. Int J Mol Sci,2023,24(7):6838.
[36] Sato T,Aizawa Y,Yuasa S,et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices:an ad-hoc analysis of the previous randomized clinical trial[J]. J Atheroscler Thromb,2020,27(12):1348-1358.
[37] Myasoedova VA,Parisi V,Moschetta D,et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue:a systematic review and meta-analysis[J]. Cardiovasc Diabetol,2023,22(1):23.
[38] Mullens W,Martens P. Empagliflozin-induced changes in epicardial fat:the centerpiece for myocardial protection?[J]. JACC Heart Fail,2021 ,9(8):590-593.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(3):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(3):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(3):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]唐欣 罗素新.心房颤动合并 射血分数保留的心力衰竭的研究进展[J].心血管病学进展,2019,(5):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
TANG Xin,LUO Suxin.Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(3):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]